Schedule 13D ownership disclosure

PELTHOS THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 171126204

Event date: 2026-10-30

Filing-level shares
5,189,177.10
Percent of class
49.9%
  • Ligand Pharmaceuticals IncorporatedReported CIK 0000886163

    Shares: 5,189,177.10 · Class: 49.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-445875
Form type
SCHEDULE 13D/A
Filer
Pelthos Therapeutics Inc.
CIK
CIK 1919246
Filed
Nov 03, 2026
Reporting period
Oct 30, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub